Affluent Medical secures its financing until the end of 2025

Affluent Medical, a French company specializing in the development of implantable medical devices, is extending its cash flow horizon until the end of 2025. This financing is made possible through the issuance of €5.4 million in convertible bonds, subscribed by its main shareholders.

The funds will enable continued clinical and regulatory development, particularly with Edwards Lifesciences for the KaliosTM device, and to prepare for the commercialization of Artus. The funding covers half of the estimated €11 million requirement for the following year.

Affluent Medical also plans to pursue other financing options to ensure its viability beyond January 2026, such as industrial partnerships and non-dilutive financing.